Long-read sequencing for non-small-cell lung cancer genomes
Author(s) -
Yoshitaka Sakamoto,
Liu Xu,
Masahide Seki,
Toshiyuki Yokoyama,
Masahiro Kasahara,
Yukie Kashima,
Akihiro Ohashi,
Yoko Shimada,
Noriko Motoi,
Katsuya Tsuchihara,
Susumu Kobayashi,
Takashi Kohno,
Yuichi Shiraishi,
Ayako Suzuki,
Yutaka Suzuki
Publication year - 2020
Publication title -
genome research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 9.556
H-Index - 297
eISSN - 1549-5469
pISSN - 1088-9051
DOI - 10.1101/gr.261941.120
Subject(s) - biology , genetics , chromothripsis , genome , cancer genome sequencing , transcriptome , computational biology , gene , structural variation , epigenome , lung cancer , exome sequencing , point mutation , dna sequencing , cancer , mutation , genomics , genome instability , dna , dna damage , dna methylation , medicine , gene expression
Here, we report the application of a long-read sequencer, PromethION, for analyzing human cancer genomes. We first conducted whole-genome sequencing on lung cancer cell lines. We found that it is possible to genotype known cancerous mutations, such as point mutations. We also found that long-read sequencing is particularly useful for precisely identifying and characterizing structural aberrations, such as large deletions, gene fusions, and other chromosomal rearrangements. In addition, we identified several medium-sized structural aberrations consisting of complex combinations of local duplications, inversions, and microdeletions. These complex mutations occurred even in key cancer-related genes, such as STK11 , NF1 , SMARCA4 , and PTEN . The biological relevance of those mutations was further revealed by epigenome, transcriptome, and protein analyses of the affected signaling pathways. Such structural aberrations were also found in clinical lung adenocarcinoma specimens. Those structural aberrations were unlikely to be reliably detected by conventional short-read sequencing. Therefore, long-read sequencing may contribute to understanding the molecular etiology of patients for whom causative cancerous mutations remain unknown and therapeutic strategies are elusive.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom